Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market by Product & Service (Reagents, Kits), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (Immunodiagnostics, NGS, PCR, ISH, INAAT), Disease (Hepatitis, HIV, HAI, HPV, Syphilis, TB, Flu) & Region - Global Forecast to 2028

Report Code: MD 3088 Jan, 2024, by marketsandmarkets.com

The global infectious disease diagnostics market in terms of revenue was estimated to be worth $21.4 billion in 2023 and is poised to reach $31.5 billion by 2028, growing at a CAGR of 8.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Government initiatives, schemes, or funding that support and promote the innovation and development of the diagnostics market provide growth opportunities in the market. These financial incentives and support systems enable companies/institutes to invest in R&D, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers can push the boundaries of diagnostics, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine.

Infectious Disease Diagnostics Market Market Size, Dynamics & Ecosystem

Infectious Disease Diagnostics Market Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Infectious Disease Diagnostics Market Dynamics

DRIVER: Rising prevalence of infectious diseases

Diseases such as tuberculosis, HIV/AIDS, hepatitis, sexually transmitted infections, and respiratory infections require an accurate and timely diagnosis for effective treatment and control. Early diagnosis of these diseases plays a crucial role in the monitoring of these infectious diseases, driving the growth of the market in this area.

RESTRAINT: Unfavorable reimbursement scenario

Inadequate reimbursements are a major factor restraining the growth of the market. According to MedPAC (Medicare Payment Advisory Commission), medical testing has seen a 40% decline in reimbursement over the last 40 years. This decline and additional budgetary concerns among healthcare systems are major obstacles to implementing novel diagnostic techniques in clinical laboratories.

OPPORTUNITY: Increased growth opportunities in emerging economies

Emerging economies such as India, Brazil, Turkey, Russia, and South Africa are expected to offer potential growth opportunities for major players operating in the market. This can be attributed to the high disease prevalence, large patient population, improved healthcare infrastructure, increased disposable income, and growing medical tourism. In addition to the factors mentioned above, the Asia Pacific region has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.

CHALLENGE: Operational barriers and shortage of skilled laboratory technicians

Clinical laboratories in key markets are undergoing continuous evolution, and technicians encounter operational challenges in guaranteeing the efficient procurement, storage, and transportation of samples. This is particularly true when incorporating innovative technologies like Next-Generation Sequencing (NGS) and lab-on-a-chip PCR devices. Additionally, laboratory spaces must be reconfigured to align with the demands of conducting specific diagnostic tests for infectious diseases, ensuring pathogen detection while preventing cross-contamination and optimizing time efficiency. Therefore, there is a significant increase in costs associated with maintaining and operating advanced infectious disease diagnostic instruments, especially those designed to handle a single sample type.

Infectious Disease Diagnostics Market Segmentation & Geographical Spread

Infectious Disease Diagnostics Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

Reagents, kits, and consumables segment accounted for the largest share of the infectious disease diagnostics industry in 2022, by product & service.

The infectious disease diagnostics market is categorized into reagents, kits, and consumables; instruments; and software & services, based on product & service. The reagents, kits, and consumables segment emerged as the dominant force in the market in 2022. The versatility of reagents and kits in accommodating diverse testing needs contributes to their extensive usage and market demand. Moreover, with the growing prevalence of diseases and the need for accurate and timely diagnoses, the volume of infectious disease diagnostics tests is consistently increasing. Reagents and kits play a critical role in accommodating this rise in test volumes, ensuring an ongoing demand for these consumables. The availability of advanced reagents and kits that offer enhanced performance and reliability fosters their widespread adoption and contributes to the growth of the segment.

Hepatitis segment accounted for the largest share in the infectious disease diagnostics industry in 2022, by disease type.

The global infectious disease diagnostics market is categorized into hepatitis, HIV, hospital-acquired infections, Chlamydia trachomatis, Neisseria gonorrhea, HPV, tuberculosis, influenza, syphilis, mosquito-borne diseases, and other infectious diseases based on disease type. The hepatitis segment accounted for the largest share of the market in 2022. The global impact of hepatitis in terms of morbidity, mortality, and economic burden has contributed to a greater emphasis on developing diagnostic tools for these infections. Many countries have implemented hepatitis B vaccination programs to prevent new infections. As a result, there is a focus on early screening and diagnostics to identify and manage existing cases.

Laboratory testing segment accounted for the largest share in the infectious disease diagnostics industry in 2022, by type of testing.

The infectious disease diagnostics market has been segmented into laboratory testing and PoC testing, based on the type of testing. In 2022, the laboratory testing segment accounted for the largest share of the market. Laboratory tests generally have higher sensitivity and specificity compared to PoC tests. The controlled laboratory environment allows for more accurate and precise measurements, reducing the chances of false-negative or false-positive results. This is particularly crucial in infectious disease diagnostics, where accuracy is paramount for appropriate treatment and containment measures. Another advantage of lab tests is the ability to process a large volume of samples simultaneously. Automated platforms and high-throughput systems in laboratories can handle a high sample throughput, enabling efficient testing for infectious diseases. Such factors are expected to fuel the growth of this segment.

North America accounted for the largest share of the infectious disease diagnostics industry in 2022.

The infectious disease diagnostics market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the infectious disease diagnostics industry. The region has a robust infrastructure for R&D. Also, North America houses several major companies operating in the infectious disease diagnostics sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Also, the high burden of infectious diseases on regional healthcare systems is another major driver for market growth.

The major players in infectious disease diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), bioMérieux (France), Siemens Healthineers AG (Germany), and Danaher (US). These players lead the market because of their extensive product portfolios and wide geographic presence.

Scope of the Infectious Disease Diagnostics Industry

Report Metric

Details

Market Revenue in 2023

$21.4 billion

Projected Revenue by 2028

$31.5 billion

Revenue Rate

Poised to Grow at a CAGR of 8.0%

Market Driver

Rising prevalence of infectious diseases

Market Opportunity

Increased growth opportunities in emerging economies

This report categorizes the infectious disease diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

  • Reagents, Kits, and Consumables
  • Instruments
  • Software & Services

By Type of Testing

  • Laboratory Testing
  • PoC Testing

By Technology

By Disease Type

  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Other Hepatitis Diseases
  • HIV
  • Hospital-acquired Infections
  • Mosquito-borne Diseases
  • HPV
  • Chlamydia trachomatis
  • Neisseria gonorrhea
  • Tuberculosis
  • Influenza
  • Syphilis
  • Other Infectious Diseases

By Sample Type

  • Blood, Serum, and Plasma
  • Urine
  • Other Sample Types

By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa
    • GCC Countries
    • Rest of Middle East & Africa

Recent Developments of Infectious Disease Diagnostics Industry

  • In January 2023, Thermo Fisher Scientific Inc. (US) launched its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit.
  • In July 2022, Roche launched Elecsys HCV Duo, an immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample.
  • In September 2022, Siemens Healthineers released its CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Test.
  • In December 2021, Roche completed a purchase agreement with TIB Molbiol (Germany) to expand the PCR-test portfolio in the fight against new infectious diseases.
  • In February 2020, Cepheid collaborated with Sherlock Biosciences (US). This collaboration between the two companies aimed to explore the development of new cutting-edge molecular diagnostic tests for infectious diseases leveraging CRISPR technology.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 33)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 STUDY SCOPE 
           1.4.1 MARKETS COVERED
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 RESEARCH LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 39)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN METHODOLOGY
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.2.2.1 Key data from primary sources
           2.2.3 KEY INDUSTRY INSIGHTS
                    2.2.3.1 Breakdown of primary interviews
                    FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
           2.3.2 COMPANY REVENUE ESTIMATION APPROACH
                    FIGURE 5 COMPANY REVENUE ESTIMATION APPROACH: INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE
           2.3.3 PRESENTATIONS OF COMPANIES AND PRIMARY INTERVIEWS
           2.3.4 GROWTH FORECAST
           2.3.5 CAGR PROJECTIONS
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.6 TOP-DOWN APPROACH
                    FIGURE 7 TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ASSESSMENT 
    2.6 STUDY ASSUMPTIONS 
           2.6.1 GROWTH RATE ASSUMPTIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.8 IMPACT OF RECESSION ON MARKET 
 
3 EXECUTIVE SUMMARY (Page No. - 53)
    FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
 
4 PREMIUM INSIGHTS (Page No. - 60)
    4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 16 GROWING PREVALENCE OF INFECTIOUS DISEASE AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET
    4.2 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 
          FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.3 MARKET, BY TYPE OF TESTING, 2023 VS. 2028 (USD MILLION) 
          FIGURE 18 LABORATORY TESTING TO DOMINATE MARKET DURING STUDY PERIOD
    4.4 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD MILLION) 
          FIGURE 19 BLOOD, SERUM, AND PLASMA TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD
    4.5 MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 
          FIGURE 20 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
    4.6 MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION) 
          FIGURE 21 HEPATITIS TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
    4.7 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 
          FIGURE 22 DIAGNOSTIC LABORATORIES TO DOMINATE MARKET DURING STUDY PERIOD
    4.8 REGIONAL GROWTH OPPORTUNITIES 
          FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 65)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 24 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of infectious diseases
                    5.2.1.2 Rising focus on R&D and funding for infectious disease diagnostic products
                    5.2.1.3 Growing awareness for early disease diagnosis in emerging economies
                    5.2.1.4 Adoption of new and advanced technologies for infectious disease diagnosis
                    5.2.1.5 Shift in focus from centralized laboratories to decentralized PoC testing centers
           5.2.2 RESTRAINTS
                    5.2.2.1 Unfavorable reimbursement scenario
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increased growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Changing regulatory landscape
                    5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
    5.3 PRICING ANALYSIS 
          TABLE 2 INDICATIVE PRICING FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
          TABLE 3 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION
    5.4 PATENT ANALYSIS 
          FIGURE 25 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022)
          TABLE 4 LIST OF MAJOR PATENTS, JANUARY 2021–DECEMBER 2022
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 27 SUPPLY CHAIN ANALYSIS: MARKET
    5.7 ECOSYSTEM MARKET MAP 
          FIGURE 28 ECOSYSTEM MARKET MAP: MARKET
          TABLE 5 ROLE IN ECOSYSTEM
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 THREAT OF SUBSTITUTES
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 INTENSITY OF COMPETITIVE RIVALRY
    5.9 REGULATORY LANDSCAPE 
           5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.9.2 NORTH AMERICA
                    5.9.2.1 US
                    5.9.2.2 Canada
           5.9.3 EUROPE
                    TABLE 11 EUROPE: CLASSIFICATION OF DEVICES
           5.9.4 ASIA PACIFIC
                    5.9.4.1 China
                    5.9.4.2 Japan
                                TABLE 12 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.9.4.3 India
           5.9.5 LATIN AMERICA
                    5.9.5.1 Brazil
                    5.9.5.2 Mexico
           5.9.6 MIDDLE EAST
                    5.9.6.1 Africa
    5.10 TRADE ANALYSIS 
           TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
           TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
    5.11 TECHNOLOGY ANALYSIS 
    5.12 KEY CONFERENCES & EVENTS 
           TABLE 15 DETAILED LIST OF KEY CONFERENCES & EVENTS IN 2O22–2023
    5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 29 REVENUE SHIFT IN MARKET
    5.14 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
                     TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
           5.14.2 BUYING CRITERIA
                     FIGURE 31 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
                     TABLE 17 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
    5.15 CASE STUDY ANALYSIS 
           FIGURE 32 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
 
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE (Page No. - 93)
    6.1 INTRODUCTION 
          TABLE 18 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
          TABLE 19 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2022
    6.2 REAGENTS, KITS, AND CONSUMABLES 
           6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO DRIVE MARKET
                    TABLE 20 MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS WITH MINIMUM HUMAN INTERVENTION TO DRIVE MARKET
                    TABLE 21 KEY INSTRUMENTS AVAILABLE IN MARKET
                    TABLE 22 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
    6.4 SOFTWARE & SERVICES 
           6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS AND INCREASING COMPETITIVENESS FOR VALUE-ADDED SERVICES TO DRIVE MARKET
                    TABLE 23 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021–2028 (USD MILLION)
 
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY TYPE OF TESTING (Page No. - 100)
    7.1 INTRODUCTION 
          TABLE 24 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TYPE OF TESTING, 2021–2028 (USD MILLION)
           7.1.1 PRIMARY NOTES
                    FIGURE 33 KEY INDUSTRY INSIGHTS: MARKET, BY TYPE OF TESTING
    7.2 LABORATORY TESTING 
           7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET
                    TABLE 25 MARKET FOR LABORATORY TESTING, BY REGION, 2021–2028 (USD MILLION)
    7.3 POC TESTING 
           7.3.1 FASTER TURNAROUND TIME AND MORE EFFICIENT TREATMENT OPTIONS TO DRIVE MARKET
                    TABLE 26 MARKET FOR POC TESTING, BY REGION, 2021–2028 (USD MILLION)
 
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET PREDICTION, BY SAMPLE TYPE (Page No. - 105)
    8.1 INTRODUCTION 
          TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
           8.1.1 PRIMARY NOTES
                    FIGURE 34 KEY INDUSTRY INSIGHTS: MARKET, BY SAMPLE TYPE
    8.2 BLOOD, SERUM, AND PLASMA 
           8.2.1 HIGHER VERSATILITY, GREATER CLINICAL EFFICACY, AND BETTER REIMBURSEMENT POLICIES TO DRIVE MARKET
                    TABLE 28 MARKET FOR BLOOD, SERUM, AND PLASMA, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 NON-INVASIVE NATURE OF URINE SAMPLES TO DRIVE MARKET
                    TABLE 29 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.4 OTHER SAMPLE TYPES 
          TABLE 30 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
 
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET PREDICTION, BY DISEASE TYPE (Page No. - 110)
    9.1 INTRODUCTION 
          TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY DISEASE TYPE, 2021–2028 (USD MILLION)
    9.2 HEPATITIS 
          TABLE 32 MARKET FOR HEPATITIS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 33 MARKET FOR HEPATITIS, BY REGION, 2021–2028 (MILLION TESTS)
          TABLE 34 MARKET FOR HEPATITIS, BY METHOD, 2021–2028 (USD MILLION)
          TABLE 35 MARKET FOR HEPATITIS, BY TYPE, 2021–2028 (USD MILLION)
           9.2.1 HEPATITIS B
                    9.2.1.1 Increasing global prevalence of hepatitis B to drive segment
                                TABLE 36 HEPATITIS B MARKET, BY REGION, 2021–2028 (USD MILLION)
           9.2.2 HEPATITIS C
                    9.2.2.1 Rising number of government initiatives for hepatitis C diagnosis to drive segment
                                TABLE 37 HEPATITIS C MARKET, BY REGION, 2021–2028 (USD MILLION)
           9.2.3 OTHER HEPATITIS DISEASES
                    TABLE 38 OTHER HEPATITIS DISEASES MARKET, BY REGION, 2021–2028 (USD MILLION)
    9.3 HIV 
           9.3.1 GROWING PREVALENCE OF AIDS AND INCREASING AVAILABILITY OF HIV POC TESTING TO DRIVE MARKET
                    TABLE 39 MARKET FOR HIV, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 40 MARKET FOR HIV, BY REGION, 2021–2028 (MILLION TESTS)
    9.4 HOSPITAL-ACQUIRED INFECTIONS 
           9.4.1 RISING BURDEN OF INFECTIONS AND INCREASING ADOPTION OF ADVANCED DIAGNOSTIC TESTS TO DRIVE MARKET
                    TABLE 41 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 42 MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2021–2028 (MILLION TESTS)
    9.5 MOSQUITO-BORNE DISEASES 
           9.5.1 RISING INCIDENCE OF DENGUE AND MALARIA AND INCREASING NUMBER OF AWARENESS PROGRAMS TO DRIVE MARKET
                    TABLE 43 MAJOR PRODUCTS FOR DENGUE TESTING AVAILABLE IN MARKET
                    TABLE 44 MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2021–2028 (USD MILLION)
    9.6 HPV 
           9.6.1 TECHNOLOGICAL ADVANCEMENTS FOR PREVENTING HPV INFECTIONS TO DRIVE MARKET
                    TABLE 45 MARKET FOR HPV, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 46 MARKET FOR HPV, BY REGION, 2021–2028 (MILLION TESTS)
    9.7 CHLAMYDIA TRACHOMATIS 
           9.7.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET
                    TABLE 47 MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 48 MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2021–2028 (MILLION TESTS)
    9.8 NEISSERIA GONORRHEA 
           9.8.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET
                    TABLE 49 MARKET FOR NEISSERIA GONORRHEA, BY REGION, 2021–2028 (USD MILLION)
    9.9 TUBERCULOSIS 
           9.9.1 INCREASING BURDEN OF TUBERCULOSIS IN UNDERDEVELOPED NATIONS TO DRIVE MARKET
                    TABLE 50 MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 51 MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (MILLION TESTS)
                    TABLE 52 MARKET FOR TUBERCULOSIS, BY METHOD, 2021–2028 (USD MILLION)
    9.10 INFLUENZA 
           9.10.1 RISING FOCUS ON FASTER DIAGNOSIS AND CONTROL TO DRIVE MARKET
                     TABLE 53 MARKET FOR INFLUENZA, BY REGION, 2021–2028 (USD MILLION)
                     TABLE 54 MARKET FOR INFLUENZA, BY REGION, 2021–2028 (MILLION TESTS)
                     TABLE 55 MARKET FOR INFLUENZA, BY METHOD, 2021–2028 (USD MILLION)
    9.11 SYPHILIS 
           9.11.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES FOR IMPROVED SCREENING TO DRIVE MARKET
                     TABLE 56 MARKET FOR SYPHILIS, BY REGION, 2021–2028 (USD MILLION)
    9.12 OTHER INFECTIOUS DISEASES 
           TABLE 57 MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
    9.13 COVID-19 
           9.13.1 DECLINING CASES OF COVID-19 TO LIMIT MARKET
                     TABLE 58 MARKET FOR COVID-19, BY REGION, 2021–2028 (USD MILLION)
 
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET PREDICTION, BY TECHNOLOGY (Page No. - 131)
     10.1 INTRODUCTION 
     10.2 PRIMARY NOTES 
             FIGURE 35 KEY INDUSTRY INSIGHTS: INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY TECHNOLOGY
             TABLE 59 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
     10.3 IMMUNODIAGNOSTICS 
             10.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
                        TABLE 60 MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
     10.4 CLINICAL MICROBIOLOGY 
             10.4.1 QUICKER TURNAROUND TIME FOR RESULTS WITH HIGHER SENSITIVITY AND RELIABILITY TO DRIVE MARKET
                        TABLE 61 MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2021–2028 (USD MILLION)
     10.5 POLYMERASE CHAIN REACTION 
             10.5.1 EASE OF USE, COST-EFFECTIVENESS, AND HIGH SPECIFICITY TO DRIVE MARKET
                        TABLE 62 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2021–2028 (USD MILLION)
     10.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 
             10.6.1 LOWER COST AND BETTER SUITABILITY FOR POINT-OF-CARE TESTING TO DRIVE MARKET
                        TABLE 63 MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION)
     10.7 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 
             10.7.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND INCREASED FOCUS ON MOLECULAR TARGETED DRUGS TO DRIVE MARKET
                        TABLE 64 MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
     10.8 DNA MICROARRAY 
             10.8.1 HIGH INSTRUMENT COSTS AND NEED FOR EXPERT TECHNICIANS TO LIMIT MARKET
                        TABLE 65 MARKET FOR DNA MICROARRAY, BY REGION, 2021–2028 (USD MILLION)
     10.9 OTHER TECHNOLOGIES 
             TABLE 66 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
 
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET PREDICTION, BY END USER (Page No. - 141)
     11.1 INTRODUCTION 
             TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     11.2 DIAGNOSTIC LABORATORIES 
             11.2.1 DEVELOPMENT OF LOW-COST AND HIGHLY SPECIALIZED SCREENING TESTS TO DRIVE MARKET
                        TABLE 68 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     11.3 HOSPITALS & CLINICS 
             11.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS AND BETTER REIMBURSEMENT FACILITIES TO DRIVE MARKET
                        TABLE 69 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION)
     11.4 ACADEMIC RESEARCH INSTITUTES 
             11.4.1 INCREASING FOCUS ON R&D FOR DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET
                        TABLE 70 MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
     11.5 OTHER END USERS 
             TABLE 71 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
12 INFECTIOUS DISEASE DIAGNOSTICS MARKET PREDICTION, BY REGION (Page No. - 147)
     12.1 INTRODUCTION 
             TABLE 72 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     12.2 NORTH AMERICA 
             FIGURE 36 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
             TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 74 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 75 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 76 NORTH AMERICA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
             TABLE 77 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.1 NORTH AMERICA: RECESSION IMPACT
             12.2.2 US
                        12.2.2.1 Increasing prevalence of infectious diseases to drive market
                                      TABLE 78 US: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 79 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 80 US: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 81 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.2.3 CANADA
                        12.2.3.1 Focus on affordable tests and use of personalized medicine to drive market
                                      TABLE 82 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 83 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 84 CANADA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 85 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.3 EUROPE 
             TABLE 86 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 87 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 88 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 89 EUROPE: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
             TABLE 90 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.1 EUROPE: RECESSION IMPACT
             12.3.2 GERMANY
                        12.3.2.1 Increasing healthcare expenditure and rising per capita disposable income to drive market
                                      TABLE 91 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 92 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 93 GERMANY: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 94 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.3 UK
                        12.3.3.1 Growing number of accredited diagnostic and hospital laboratories to drive market
                                      TABLE 95 UK: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 96 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 97 UK: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 98 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.4 FRANCE
                        12.3.4.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market
                                      TABLE 99 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 100 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 101 FRANCE: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 102 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.5 ITALY
                        12.3.5.1 Increased adoption of advanced diagnostic technologies and growing government healthcare investment to drive market
                                      TABLE 103 ITALY: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 104 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 105 ITALY: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.6 SPAIN
                        12.3.6.1 Rising geriatric population and improving healthcare infrastructure to drive market
                                      TABLE 107 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 108 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 109 SPAIN: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 110 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.3.7 REST OF EUROPE
                        TABLE 111 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
                        TABLE 112 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 113 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 114 REST OF EUROPE: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                        TABLE 115 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.4 ASIA PACIFIC 
             FIGURE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
             TABLE 116 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 117 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 118 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 119 ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
             TABLE 120 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.1 ASIA PACIFIC: RECESSION IMPACT
             12.4.2 CHINA
                        12.4.2.1 Increased public access to modern healthcare and favorable government policies to drive market
                                      TABLE 121 CHINA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 122 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 123 CHINA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 124 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.3 JAPAN
                        12.4.3.1 Presence of well-developed healthcare system and universal reimbursement policies to drive market
                                      TABLE 125 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 126 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 127 JAPAN: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 128 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.4 INDIA
                        12.4.4.1 Increasing private and public investments in healthcare system to drive market
                                      TABLE 129 INDIA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 130 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 131 INDIA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 132 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.4.5 REST OF ASIA PACIFIC
                        TABLE 133 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 134 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 135 REST OF ASIA PACIFIC: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                        TABLE 136 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     12.5 LATIN AMERICA 
             12.5.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET
                        TABLE 137 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 138 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 139 LATIN AMERICA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                        TABLE 140 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.5.2 LATIN AMERICA: RECESSION IMPACT
     12.6 MIDDLE EAST & AFRICA 
             TABLE 141 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 142 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 143 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 144 MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
             TABLE 145 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
             12.6.2 GCC COUNTRIES
                        12.6.2.1 Rising focus on advanced health infrastructure to drive market
                                      TABLE 146 GCC COUNTRIES: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 147 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 148 GCC COUNTRIES: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                                      TABLE 149 GCC COUNTRIES: MARKET, BY END USER, 2021–2028 (USD MILLION)
             12.6.3 REST OF MIDDLE EAST & AFRICA
                        TABLE 150 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 151 REST OF MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 152 REST OF MIDDLE EAST & AFRICA: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
                        TABLE 153 REST OF MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
13 COMPETITIVE LANDSCAPE (Page No. - 197)
     13.1 OVERVIEW 
     13.2 KEY STRATEGIES/RIGHT TO WIN 
             13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
                        TABLE 154 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
     13.3 REVENUE SHARE ANALYSIS 
             FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS
     13.4 MARKET SHARE ANALYSIS 
             FIGURE 39 INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
             TABLE 155 DEGREE OF COMPETITION: INFECTIOUS DISEASE DIAGNOSTICS INDUSTRY
     13.5 COMPANY EVALUATION MATRIX 
             13.5.1 STARS
             13.5.2 EMERGING LEADERS
             13.5.3 PERVASIVE PLAYERS
             13.5.4 PARTICIPANTS
                        FIGURE 40 COMPANY EVALUATION MATRIX, 2022
             13.5.5 COMPANY FOOTPRINT
                        FIGURE 41 PRODUCT AND REGIONAL FOOTPRINT OF KEY PLAYERS
                        TABLE 156 COMPANY FOOTPRINT
                        TABLE 157 PRODUCT & SERVICE FOOTPRINT
                        TABLE 158 REGIONAL FOOTPRINT
     13.6 START-UP/SME EVALUATION MATRIX 
             13.6.1 PROGRESSIVE COMPANIES
             13.6.2 RESPONSIVE COMPANIES
             13.6.3 DYNAMIC COMPANIES
             13.6.4 STARTING BLOCKS
                        FIGURE 42 START-UP/SME EVALUATION MATRIX, 2022
             13.6.5 COMPETITIVE BENCHMARKING
                        TABLE 159 DETAILED LIST OF KEY START-UPS/SMES
     13.7 COMPETITIVE SCENARIOS AND TRENDS 
             13.7.1 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
                        TABLE 160 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS, 2020–2023
             13.7.2 KEY DEALS
                        TABLE 161 KEY DEALS, 2020–2023
 
14 COMPANY PROFILES (Page No. - 210)
     14.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 162 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             14.1.2 ABBOTT
                        TABLE 163 ABBOTT: COMPANY OVERVIEW
                        FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2022)
             14.1.3 BIOMÉRIEUX
                        TABLE 164 BIOMÉRIEUX: COMPANY OVERVIEW
                        FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
             14.1.4 SIEMENS HEALTHINEERS AG
                        TABLE 165 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             14.1.5 DANAHER
                        TABLE 166 DANAHER: COMPANY OVERVIEW
                        FIGURE 47 DANAHER: COMPANY SNAPSHOT (2022)
             14.1.6 THERMO FISHER SCIENTIFIC INC.
                        TABLE 167 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 48 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             14.1.7 HOLOGIC, INC.
                        TABLE 168 HOLOGIC, INC.: COMPANY OVERVIEW
                        FIGURE 49 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
             14.1.8 BECTON, DICKINSON AND COMPANY
                        TABLE 169 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             14.1.9 REVVITY
                        TABLE 170 REVVITY: COMPANY OVERVIEW
                        FIGURE 51 REVVITY: COMPANY SNAPSHOT (2022)
             14.1.10 QIAGEN
                        TABLE 171 QIAGEN: COMPANY OVERVIEW
                        FIGURE 52 QIAGEN: COMPANY SNAPSHOT (2022)
             14.1.11 SEEGENE INC.
                        TABLE 172 SEEGENE INC.: COMPANY OVERVIEW
                        FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT (2022)
     14.2 OTHER PLAYERS 
             14.2.1 QUIDELORTHO CORPORATION
             14.2.2 GRIFOLS, S.A.
             14.2.3 DIASORIN S.P.A.
             14.2.4 BIO-RAD LABORATORIES, INC.
             14.2.5 SYSMEX CORPORATION
             14.2.6 ORASURE TECHNOLOGIES
             14.2.7 CO-DIAGNOSTICS, INC.
             14.2.8 MERIDIAN BIOSCIENCE
             14.2.9 CHEMBIO DIAGNOSTICS, INC.
             14.2.10 TRINITY BIOTECH
             14.2.11 GENETIC SIGNATURES LTD.
             14.2.12 EPITOPE DIAGNOSTICS, INC.
             14.2.13 TRIVITRON HEALTHCARE
             14.2.14 ELITECH GROUP
             14.2.15 MERIL LIFE SCIENCES PVT. LTD.
             14.2.16 INBIOS INTERNATIONAL, INC.
             14.2.17 UNIOGEN OY
             14.2.18 VELA DIAGNOSTICS
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
15 APPENDIX (Page No. - 301)
     15.1 DISCUSSION GUIDE 
     15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     15.3 CUSTOMIZATION OPTIONS 
     15.4 RELATED REPORTS 
     15.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the infectious disease diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Infectious  Disease Diagnostics Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Abbott

Sales Manager

Becton, Dickinson and Company

Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the infectious disease diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Infectious Disease Diagnostics Market Size: Botton Up Approach

Infectious  Disease Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Infectious Disease Diagnostics Market Size: Top-Down Approach

Infectious  Disease Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Infectious disease diagnostics can be defined as various techniques and products (including kits, assays, tests, reagents, and analyzers) used by healthcare professionals to detect and diagnose disease-causing pathogens in human samples such as serum, blood, urine, throat swab, and stool, among others.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global infectious disease diagnostics market by product & service, type of testing, sample type, technology, disease type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings

Available Customizations

MarketsandMarkets offers the following customizations for this market report.

Country Information

  • Additional country-level analysis

Company profiles

  • Additional five company profiles of players operating in the market.

Product Analysis

  • Product matrix, which provides a detailed comparison of the product portfolio of each company in the market
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3088
Published ON
Jan, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Infectious Disease Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback